Fresenius Med Cr Stock Price, News & Analysis

Fresenius Medical Care reported an 18% increase in operating income for 2024, reaching the upper end of its outlook range. The company achieved organic revenue growth of 4%, driven by Care Enablement and Care Delivery segments. U.S. same market treatment growth turned positive for the full year. The FME25 program delivered EUR 567 million in savings, surpassing the target, and the 2025 goal was raised to EUR 750 million. Reported net income grew by 8%, and the net financial leverage ratio improved from 3.2x to 2.9x. A 21% dividend increase is planned.

Fresenius Medical Care's strategic plan included exiting non-core assets, impacting revenue by EUR 306 million and operating income by EUR 288 million. The company reduced net financial debt by 9% to EUR 9.8 billion. Group revenue increased by 2% in Q4 2024 to EUR 5,085 million, with Care Enablement revenue growing by 11%. Operating income for Q4 decreased by 39%, but on an outlook base, it increased by 31%.

For 2025, Fresenius Medical Care expects revenue growth to be positive to a low-single digit percent rate and operating income to grow by a high-teens to high-twenties percent rate. The company treated 299,352 patients in 3,675 clinics worldwide as of December 31, 2024.

Fresenius Medical Care (XETRA: FME; NYSE: FMS), a global leader in renal disease care, announced the divestment of select assets of its wholly owned Spectra Laboratories to Quest Diagnostics (NYSE: DGX). Under the agreement, Quest will acquire laboratory assets focused on renal-specific testing in the U.S. Additionally, Quest will provide comprehensive dialysis-related lab and water testing services to Fresenius Medical Care's clinics in the U.S.

This acquisition will allow Quest to enhance its portfolio with dialysis-related water testing capabilities. The deal is expected to bring operational efficiencies to Fresenius Medical Care and leverage Quest's national scale, reducing transportation times and speeding up results reporting. Financial terms were not disclosed, and the acquisition is expected to close in the second half of 2025, with service transitions completing by early 2026.

Fresenius Medical Care is in the second year of a three-year strategic turnaround plan, focusing on optimizing its portfolio by divesting non-core and dilutive assets. Chronic kidney disease affects approximately 35.5 million people in the U.S., with over 800,000 receiving dialysis. This transaction aligns with Fresenius Medical Care's strategy to concentrate on its core business of providing dialysis care.

Fresenius Medical Care (FME), the global leader in renal disease products and services, has achieved a significant milestone by being included in the Dow Jones Sustainability World Index and, for the 15th time, in the Dow Jones Sustainability Europe Index. The company demonstrated notable progress in its sustainability targets across three strategic areas: healthcare quality enhancement, team building, and environmental footprint reduction.

Key achievements in 2023 include: improving patient satisfaction with a Net Promoter Score of 72, increasing women's representation in top management to 34%, and reducing Scope 1 and 2 emissions by 16% from 2020 levels. The company also signed virtual power purchase agreements for 580 gigawatt hours annually with wind and solar farms in Germany and the U.S., while submitting a commitment to the Science Based Target initiative.

Fresenius Medical Care (FME), the world's leading provider of kidney disease products and services, will return to Germany's DAX 40 index on December 27, 2024. The DAX 40 represents the 40 largest companies on the Frankfurt Stock Exchange, accounting for 80% of Germany's listed stock market capitalization.

FME has been listed in the Mid-Cap DAX (MDAX) since March 2023, after being a DAX member from September 1999. The company operates 3,732 dialysis clinics, serving approximately 308,000 patients globally, and is a leading provider of dialysis equipment.

Fresenius Medical Care (FMS) has secured a national group purchasing agreement with Premier, Inc. for its Novalung ECMO System. The agreement provides Premier's 4,350+ member hospitals and health systems access to pre-negotiated pricing for the system, which is FDA-cleared for long-term extracorporeal membrane oxygenation. The Novalung System pumps and oxygenates blood in patients with acute respiratory or cardiopulmonary failure, offering a portable therapy solution for various clinical settings. This strategic partnership aims to expand access to ECMO solutions nationwide and reinforces FMS's commitment to advancing critical care treatments.

Fresenius Medical Care reported strong Q3 2024 results with organic revenue growth of 2%. The company achieved operating income of EUR 463 million, up 43% year-over-year, with margin increasing to 9.7%. Key highlights include positive underlying U.S. dialysis treatment volume growth, EUR 64 million in additional FME25 savings, and improved net leverage ratio of 2.8x. The company tightened its FY 2024 operating income growth outlook to 16-18%, toward the upper end of previous guidance. Care Delivery margin extended into 2025 target band while Care Enablement maintained significant margin progress.

Fresenius Medical Care (FMS) will present nearly 75 research abstracts at the American Society of Nephrology's Kidney Week 2024. The company will showcase advancements in hemodiafiltration therapy and its potential to improve patient outcomes. Researchers will share insights from global databases on kidney failure trends, cardiovascular risks, and treatment modalities.

Key highlights include:

• Research on high-volume hemodiafiltration (HVHDF) and its impact on patient outcomes
• Studies on sustainability and equity in kidney care
• Analysis of global databases to drive care improvements
• Leveraging artificial intelligence and advanced analytics for patient care

Fresenius Medical Care received FDA 510(k) clearance for its 5008X Hemodialysis System in February 2024 and plans to introduce hemodiafiltration therapy in its U.S. clinics starting in 2025.

Fresenius Medical Care (FMS) has reached a milestone of over 14,000 U.S. patients using its NxStage systems for Home Hemodialysis (HHD). The company has also launched the NxStage® Versi®HD with GuideMe Software, a new home dialysis machine designed to simplify treatment and improve user experience. Between January and April 2024, new HHD patients starting treatment with NxStage in the U.S. grew by 18% compared to the same period in 2023. The Versi®HD with GuideMe Software, FDA-cleared in 2023, has gained significant interest from various dialysis providers. Its advanced technology aims to enhance ease of use, improve training time, and accommodate diverse learning styles.

Fresenius Medical Care reported improved financial performance in Q2 2024, with organic revenue growth of 2.3% and increased operating income and margins. Key highlights include:

• Revenue decreased 1% to €4,766 million (-2% at constant currency, +2% organic)
• Operating income increased 19% to €425 million, with margin expanding to 8.9%
• Net income grew 33% to €187 million
• FME25 program delivered €57 million in additional savings
• Portfolio optimization progressing with several divestitures closed
• Net leverage ratio improved to 3.1x
• Full year 2024 outlook confirmed

The company remains focused on its operational turnaround and strategic plan execution, with Care Enablement driving profitability improvements. Fresenius Medical Care reaffirmed its 2025 target of 10-14% operating income margin.